CYP3A4

Summary

Gene Symbol: CYP3A4
Description: cytochrome P450 family 3 subfamily A member 4
Alias: CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4, HLP, NF-25, P450C3, P450PCN1, cytochrome P450 3A4, 1,8-cineole 2-exo-monooxygenase, P450-III, steroid inducible, albendazole monooxygenase, albendazole sulfoxidase, cholesterol 25-hydroxylase, cytochrome P450 3A3, cytochrome P450 HLp, cytochrome P450 NF-25, cytochrome P450, family 3, subfamily A, polypeptide 4, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, cytochrome P450-PCN1, glucocorticoid-inducible P450, nifedipine oxidase, quinine 3-monooxygenase, taurochenodeoxycholate 6-alpha-hydroxylase
Species: human
Products:     CYP3A4

Top Publications

  1. Sata F, Sapone A, Elizondo G, Stocker P, Miller V, Zheng W, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000;67:48-56 pubmed
    ..Baculovirus-directed cDNA expression revealed that the CYP3A4*2 P450 had a lower intrinsic clearance for the CYP3A4 substrate nifedipine compared with the wild-type enzyme but ..
  2. Hsieh K, Lin Y, Cheng C, Lai M, Lin M, Siest J, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001;29:268-73 pubmed
    Human cytochrome P450 3A4 is a major P450 enzyme in the liver and gastrointestinal tract. It plays important roles in the metabolism of a wide variety of drugs, some endogenous steroids, and harmful environmental contaminants...
  3. Lemahieu W, Maes B, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant. 2004;4:1514-22 pubmed
    ..A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients...
  4. Chantarangsu S, Cressey T, Mahasirimongkol S, Capparelli E, Tawon Y, Ngo Giang Huong N, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother. 2009;64:1265-73 pubmed publisher
    ..Nine SNPs within CYP2B6, CYP3A4 and ABCB1 were genotyped by real-time PCR...
  5. Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem. 2008;283:9674-80 pubmed publisher
    ..the inducible expression of a variety of transporters and drug-metabolizing enzymes, including CYP3A4 (cytochrome P450 3A4)...
  6. Johnson N, Walker K, Gibson L, Orr N, Folkerd E, Haynes B, et al. CYP3A variation, premenopausal estrone levels, and breast cancer risk. J Natl Cancer Inst. 2012;104:657-69 pubmed publisher
    ..This association may have wider implications given that the most predominantly expressed CYP3A gene, CYP3A4, is responsible for metabolism of endogenous and exogenous hormones and hormonal agents used in the treatment of ..
  7. Cabrera S, Santos D, Valverde M, Dominguez Gil A, Gonzalez F, Luna G, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53:2791-8 pubmed publisher
    ..In a subgroup of 32 patients, genetic polymorphisms of the cytochrome P450 2B6 gene (CYP2B6), CYP3A4, and MDR1 were also investigated. Efavirenz oral clearance and the apparent volume of distribution were 9...
  8. Elens L, Yombi J, Lison D, Wallemacq P, Vandercam B, Haufroid V. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics. 2009;10:1589-97 pubmed publisher
    ..Further investigations are needed to confirm this association and to explore its real pharmacodynamic impact. ..
  9. Wang D, Guo Y, Wrighton S, Cooke G, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274-86 pubmed publisher
    b>Cytochrome P450 3A4 (CYP3A4) metabolizes ?50% of all clinically used drugs. Although CYP3A4 expression varies widely between individuals, the contribution of genetic factors remains uncertain...

More Information

Publications63

  1. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86:609-18 pubmed publisher
    ..of tacrolimus was performed using NONMEM, and the impact of variables (demographic and clinical factors, and CYP3A4-A5, ABCB1, and ABCC2 polymorphisms) was tested...
  2. Fanta S, Niemi M, Jönsson S, Karlsson M, Holmberg C, Neuvonen P, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics. 2008;18:77-90 pubmed publisher
    To evaluate whether variations in the ABCB1, ABCC2, SLCO1B1, CYP3A4, CYP3A5, or NR1I2 genes are associated with the pharmacokinetics of cyclosporine in pediatric renal transplant candidates, and whether the effects of these variants are ..
  3. Ekhart C, Doodeman V, Rodenhuis S, Smits P, Beijnen J, Huitema A. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008;18:515-23 pubmed publisher
    ..The purpose of this study was to evaluate the effects of known allelic variants in the CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1 genes on the pharmacokinetics of the anticancer agent, cyclophosphamide,..
  4. Press R, Ploeger B, Den Hartigh J, van der Straaten T, van Pelt J, Danhof M, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187-97 pubmed publisher
    ..albumin concentration, prednisolone dose, TRL dose interval, polymorphisms in genes coding for ABCB1, CYP3A5, CYP3A4, and the pregnane X receptor on TRL pharmacokinetics...
  5. Innocenti F, Kroetz D, Schuetz E, Dolan M, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27:2604-14 pubmed publisher
    ..On the basis of this exploratory analysis, common polymorphisms in genes encoding for ABC and SLC transporters may have a significant impact on the pharmacokinetics and pharmacodynamics of CPT-11. Confirmatory studies are required. ..
  6. Qiu H, Mathäs M, Nestler S, Bengel C, Nem D, Gödtel Armbrust U, et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenet Genomics. 2010;20:167-78 pubmed publisher
    The individually variable and unpredictable expression of CYP3A4 compromises therapies with 50% of contemporary drugs. Gene variants explain only a fraction of this variability...
  7. Kurzawski M, Dabrowska J, Dziewanowski K, Domanski L, Perużyńska M, Drozdzik M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014;15:179-88 pubmed publisher
    ..factors are considered responsible for a part of the observed pharmacokinetic variability, hereby SNPs within the CYP3A4, CYP3A5 and ABCB1 genes in kidney transplant patients of Polish Caucasian origin were investigated...
  8. Zuo X, Ng C, Barrett J, Luo A, Zhang B, Deng C, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013;23:251-61 pubmed publisher
    ..The aim of this study was to examine the association between tacrolimus pharmacokinetic variability and CYP3A4 and CYP3A5 genotypes by a population pharmacokinetic analysis based on routine drug monitoring data in adult renal ..
  9. He B, Shi L, Qiu J, Tao L, Li R, Yang L, et al. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol. 2011;108:208-13 pubmed publisher
    b>CYP3A4 is a major member of the cytochrome P450 (CYP) enzymes which play crucial roles in cardiovascular diseases. Recently, a novel polymorphism in the CYP3A4 gene, IVS10+12G>A, named CYP3A4*1G (rs2242480), has been identified...
  10. Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013;512:226-31 pubmed publisher
    ..All liver transplant recipients treated with tacrolimus were genotyped for CYP3A5 (6986A>G), CYP3A4 intron 6 (CYP3A4*22), MDR-1 exon 26 (3435C>T) and exon 12 (1236 C>T) SNPs by HRM analysis (high-resolution ..
  11. Elens L, Bouamar R, Hesselink D, Haufroid V, van der Heiden I, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574-83 pubmed publisher
    ..We used TaqMan analyses to evaluate the impact of a newly discovered CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) single-nucleotide polymorphism (SNP) (rs35599367C>T; ..
  12. Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, Rane A, et al. DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie. 2012;94:2338-44 pubmed publisher
    The CYP3A4 gene, encoding the major drug metabolizing enzyme in humans, exhibits a high interindividual variation in hepatic expression that can lead to interindividual differences in drug metabolism and associated adverse drug effects...
  13. Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol. 2009;380:169-77 pubmed publisher
    The present study investigated pharmacogenetic associations of common cytochrome P450 3A (CYP3A5 and CYP3A4) polymorphisms with dose requirements of calcineurin inhibitors, cyclosporine (CsA) and tacrolimus (Tac) in renal transplant ..
  14. Cooper B, Cho T, Thompson P, Wallace A. Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression. Toxicol Sci. 2008;103:268-77 pubmed publisher
    b>Cytochrome P450 3A4 (CYP3A4) is responsible for oxidative metabolism of more than 60% of all pharmaceuticals...
  15. Baker S, Verweij J, Cusatis G, van Schaik R, Marsh S, Orwick S, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85:155-63 pubmed publisher
    ..17). However, the simultaneous presence of the CYP3A4*1B and CYP3A5*1A alleles was associated with a 64% increase in docetaxel clearance (P = 0...
  16. Crettol S, Venetz J, Fontana M, Aubert J, Pascual M, Eap C. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008;30:689-99 pubmed publisher
    ..2; 95% confidence interval = 1.4-37.3; P = 0.009). CYP3A4 rs4646437C>T influenced cyclosporine kinetics, the T carriers requiring higher cyclosporine dose...
  17. Haas D, Gebretsadik T, Mayo G, Menon U, Acosta E, Shintani A, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis. 2009;199:872-80 pubmed publisher
    ..Exploratory analyses involved another 51 polymorphisms in CYP2B6, ABCB1, CYP3A4, and CYP3A5...
  18. Elens L, Bouamar R, Hesselink D, Haufroid V, van Gelder T, van Schaik R. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22:373-80 pubmed publisher
    Cyclosporine A (CsA) is a substrate of cytochrome P450 3A4 (CYP3A4)...
  19. Fahmi O, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, et al. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos. 2009;37:1658-66 pubmed publisher
    b>Cytochrome P450 3A4 (CYP3A4) is the most important enzyme in drug metabolism and because it is the most frequent target for pharmacokinetic drug-drug interactions (DDIs) it is highly desirable to be able to predict CYP3A4-based DDIs from ..
  20. Mitra R, Guo Z, Milani M, Mesaros C, RODRIGUEZ M, Nguyen J, et al. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011;286:17543-59 pubmed publisher
    b>CYP3A4 expression in breast cancer correlates with decreased overall survival, but the mechanisms are unknown...
  21. Bhatnagar V, Garcia E, O Connor D, Brophy V, Alcaraz J, Richard E, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31:95-103 pubmed publisher
    To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = ..
  22. Istrate M, Nussler A, Eichelbaum M, Burk O. Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding. Biochem Biophys Res Commun. 2010;393:688-93 pubmed publisher
    Induction of the major drug metabolizing enzyme CYP3A4 by xenobiotics contributes to the pronounced interindividual variability of its expression and often results in clinically relevant drug-drug interactions...
  23. Spurdle A, Goodwin B, Hodgson E, Hopper J, Chen X, Purdie D, et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 2002;12:355-66 pubmed
    b>CYP3A4 is involved in the metabolism of endogenous steroids, and an allelic variant, CYP3A4*1B, consisting of an A to G polymorphism within the 5'-flanking region termed the nifedipine-specific response element (NFSE) has been associated ..
  24. Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, et al. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics. 2006;7:831-41 pubmed
    b>Cytochrome P450 3A4 (CYP3A4) is a major CYP enzyme in the liver and intestine. It is involved in the metabolism of over 50% of all drugs currently in use...
  25. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem. 1993;218:585-95 pubmed
    ..Nagashima, K. & Kamataki, T. (1990) Biochemistry 29, 4430-4433]. The sequences of three genomic clones for CYP3A4 were analyzed for all exons, exon-intron junctions and the 5'-flanking region from the major transcription site to ..
  26. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001;11:111-21 pubmed
    ..The 231 kb locus sequence contains the three CYP3A genes described previously (CYP3A4, CYP3A5 and CYP3A7), three pseudogenes as well as a novel CYP3A gene termed CYP3A43...
  27. Bosch T, Doodeman V, Smits P, Meijerman I, Schellens J, Beijnen J. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diagn Ther. 2006;10:175-85 pubmed
    ..this study was to explore the frequencies of polymorphisms in drug-metabolizing enzymes (CYP1A1, CYP2C9, CYP2C19, CYP3A4, CYP2D6, CYP3A5, DPYD, UGT1A1, GSTM1, GSTP1, GSTT1) and drug transporters (ABCB1[MDR1] and ABCC2[MRP2]), and to ..
  28. Garsa A, McLeod H, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet. 2005;6:19 pubmed
    Human cytochrome P450 3A enzymes, particularly CYP3A4 and CYP3A5, play an important role in drug metabolism. CYP3A expression exhibits substantial interindividual variation, much of which may result from genetic variation...
  29. Kittles R, Chen W, Panguluri R, Ahaghotu C, Jackson A, Adebamowo C, et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?. Hum Genet. 2002;110:553-60 pubmed
    b>CYP3A4-V, an A to G promoter variant associated with prostate cancer in African Americans, exhibits large differences in allele frequency between populations...
  30. Haas D, Ribaudo H, Kim R, Tierney C, Wilkinson G, Gulick R, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400 pubmed
    ..Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics...
  31. Keshava C, McCanlies E, Weston A. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 2004;160:825-41 pubmed
    The steroid hydroxylase CYP3A4 is the most abundant P-450 enzyme in the human liver, and CYP3A enzymes metabolize more than 50% of prescription drugs. The CYP3A4 gene is expressed in the liver, gut, colon, prostate, and breast...
  32. Floyd M, Gervasini G, Masica A, Mayo G, George A, Bhat K, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 2003;13:595-606 pubmed
    ..individuals and it has been suggested that this has a genetic basis, possibly related to variant alleles in CYP3A4 and CYP3A5 genes...
  33. Plummer S, Conti D, Paris P, Curran A, Casey G, Witte J. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:928-32 pubmed
    Previous case-only studies have shown that men with the CYP3A4*1B promoter variant are at an increased risk of developing more aggressive forms of prostate cancer...
  34. Felix C, Walker A, Lange B, Williams T, Winick N, Cheung N, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A. 1998;95:13176-81 pubmed
    ..There is a polymorphism in the 5' promoter region of the CYP3A4 gene (CYP3A4-V) that might alter the metabolism of anticancer drugs...
  35. Eiselt R, Domanski T, Zibat A, Mueller R, Presecan Siedel E, Hustert E, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001;11:447-58 pubmed
    The genetic component of the inter-individual variability in CYP3A4 activity has been estimated to be between 60% and 90%, but the underlying genetic factors remain largely unknown...
  36. Garcia Martin E, Martinez C, Pizarro R, García Gamito F, Gullsten H, Raunio H, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71:196-204 pubmed
    Our objective was to evaluate the presence of CYP3A4 gene variants in white individuals with low CYP3A4 enzyme activity...
  37. Zeigler Johnson C, Walker A, Mancke B, Spangler E, Jalloh M, McBride S, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 2002;54:13-21 pubmed
    ..Ethnic differences in genotypes for genes associated with androgen metabolism including SRD5A2 and CYP3A4 also may exist. The aim of this study was to evaluate differences in these genotypes by ethnicity...
  38. Kadlubar F, Berkowitz G, Delongchamp R, Wang C, Green B, Tang G, et al. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:327-31 pubmed
    ..High activity CYP3A4, but not CYP3A5, which primarily metabolizes testosterone, showed a striking association with the onset of puberty ..
  39. Yu B, Chen G, He N, Ouyang D, Chen X, Liu Z, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos. 2003;31:1255-9 pubmed
    The study was designed to define the contribution of cytochrome p450 2C19 (CYP2C19) and cytochrome p450 3A4 (CYP3A4) to citalopram N-demethylation and to evaluate the relationship between the disposition of citalopram and CYP2C19 ..
  40. Waxman D, Attisano C, Guengerich F, Lapenson D. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys. 1988;263:424-36 pubmed
    ..69-0.83) and with its associated nifedipine oxidase activity (r = 0...
  41. Gupta R, He Y, Patrick K, Halpert J, Bell N. CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J Clin Endocrinol Metab. 2005;90:1210-9 pubmed
    ..b>CYP3A4, a vitamin D-25-hydroxylase, and CYP1A1 had the highest 24-hydroxylase activity with 1 alpha-hydroxyvitamin D(2) (..
  42. Zeigler Johnson C, Friebel T, Walker A, Wang Y, Spangler E, Panossian S, et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004;64:8461-7 pubmed
    The CYP3A genes reside on chromosome 7q21 in a multigene cluster. The enzyme products of CYP3A4 and CYP3A43 are involved in testosterone metabolism...
  43. Rodriguez Antona C, Leskela S, Zajac M, Cuadros M, Alves J, Moneo M, et al. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood. 2007;110:3345-51 pubmed
    ..were compared with the clinical response and survival of the patients, finding that a high tumoral expression of CYP3A4 was significantly associated with a lower complete remission rate...
  44. Tayeb M, Clark C, Sharp L, Haites N, Rooney P, Murray G, et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002;9:653-5 pubmed
    ..Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been linked with PRCa. CYP3A4 may influence PRCa through its role in testosterone metabolism...
  45. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat M, Nurnberg P, et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics. 2007;8:443-53 pubmed
    ..We report associations between the hepatic CYP3A4 protein expression level, as well as its enzymatic activity, measured as verapamil N-dealkylation, and genetic ..
  46. Biggs J, Wan J, Cutler N, Hakkola J, Uusimäki P, Raunio H, et al. Transcription factor binding to a putative double E-box motif represses CYP3A4 expression in human lung cells. Mol Pharmacol. 2007;72:514-25 pubmed
    Two vital enzymes of the CYP3A subfamily, CYP3A4 and CYP3A5, are differentially expressed in the human lung. However, the molecular mechanisms that regulate tissue-selective expression of the genes are poorly understood...
  47. Fellay J, Marzolini C, Meaden E, Back D, Buclin T, Chave J, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-6 pubmed
    ..transporter (MDR1), which codes for P-glycoprotein, of genes coding for isoenzymes of cytochrome P450, CYP3A4, CYP3A5, CYP2D6, and CYP2C19, and of the gene for the chemokine receptor CCR5...
  48. Zhang X, Liu Z, Zheng J, Chen Z, Tang Z, Chen J, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant. 2005;19:638-43 pubmed
    ..Pharmacogenetic methods could be employed prospectively to help initial dose selection and to individualize immunosuppressive therapy. ..
  49. Dally H, Edler L, Jäger B, Schmezer P, Spiegelhalder B, Dienemann H, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13:607-18 pubmed
    ..The CYP3A4*1B allele has been associated with a two-fold higher promoter activity and with high-grade prostate cancers...
  50. Hesselink D, van Schaik R, van der Heiden I, van der Werf M, Gregoor P, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-54 pubmed
    ..Our objective was to determine the role of genetic polymorphisms in CYP3A4, CYP3A5, and MDR-1 with respect to interindividual variability in cyclosporine and tacrolimus pharmacokinetics...
  51. Roy J, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006;16:659-65 pubmed
    ..b>Cytochrome P450 3A4 (Cyp3A4) and Cyp3A5 are the most important contributors to tacrolimus metabolism while the P-glycoprotein ..
  52. Drocourt L, Ourlin J, Pascussi J, Maurel P, Vilarem M. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277:25125-32 pubmed
    The fully active dihydroxylated metabolite of vitamin D(3) induces the expression of CYP3A4 and, to a lesser extent, CYP2B6 and CYP2C9 genes in normal differentiated primary human hepatocytes...
  53. Wen S, Wang H, Ding Y, Liang H, Wang S. Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet Test. 2004;8:411-6 pubmed
    Human cytochrome P450 3A4 (CYP34A) plays an important role in the metabolism of many endo- and xenomaterials. It also exhibits a substantial interindividual variation in enzymatic activity...
  54. Boocock D, Brown K, Gibbs A, Sanchez E, Turteltaub K, White I. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis. 2002;23:1897-901 pubmed
    ..baculovirus expressed recombinant human CYP forms and liquid chromatography-mass spectrometry to show that only CYP3A4 is responsible for the NADPH-dependent alpha-hydroxylation of tamoxifen...